April 3, 2020 09:33 AM EDTUpdated 11:46 AM

A small, obscure biotech just won big with their IPO. In this market. Are you kidding me?

How could a small, largely unknown biotech that emerged from stealth mode just months ago with early-stage cancer programs jump onto Wall Street in the …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

TRENDING NOW

A small, obscure biotech just won big with their IPO. In this market. Are you kidding me?

This article is available only to Premium subscribers

HHS says it's pulled Covid shot guidance for healthy kids. The CDC vaccine schedule shows otherwise

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

Vertex touts promising first few months of launch for non-opioid pain drug Journavx

Vertex's next challenge for pain pill? Cracking a market dominated by cheap opioids

From weeks to days: how Aizon Intelligent Agents transform pharma validation

A small, ob­scure biotech just won big with their IPO. In this mar­ket. Are you kid­ding me?

This article is available only to Premium subscribers

HHS says it's pulled Covid shot guid­ance for healthy kids. The CDC vac­cine sched­ule shows oth­er­wise

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

Lil­ly to buy non-opi­oid pain biotech SiteOne for up to $1B

Ver­tex touts promis­ing first few months of launch for non-opi­oid pain drug Jour­navx

Ver­tex's next chal­lenge for pain pill? Crack­ing a mar­ket dom­i­nat­ed by cheap opi­oids

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A small, obscure biotech just won big with their IPO. In this market. Are you kidding me?

HHS says it's pulled Covid shot guidance for healthy kids. The CDC vaccine schedule shows otherwise

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

Vertex touts promising first few months of launch for non-opioid pain drug Journavx

Vertex's next challenge for pain pill? Cracking a market dominated by cheap opioids

From weeks to days: how Aizon Intelligent Agents transform pharma validation